Fig. 4

Targetable NTRK1 fusion identified in an infiltrating glioma. A The BCAN-NTRK1 fusion was identified by 5 of 7 fusion callers, and was the only fusion returned by the filtered overlap results. Total fusions identified by each caller are shown, FusionMap and MapSplice identified no overlapping fusions that passed filtering (0 overlaps between callers are not shown). B The BCAN-NTRK1 fusion is an intrachromosomal event occurring on 1q23.1, joining exon 6 of BCAN (blue) and exon 8 of NTRK1 (red). C This fusion results in the juxtaposition of the tyrosine kinase catalytic domain of the NTRK1 gene to the 5′ end of the BCAN gene. D NTRK1 is highly expressed in this patient (red) compared to CNS tumors (black) in the NCH cohort (CNS tumors: n = 138), with a normalized read count that is 7.70 standard deviations above the mean (131.2). E The BCAN-NTRK1 fusion is predicted to increase expression and activation of the tyrosine kinase NTRK1, which may be inhibited by TRK inhibitor therapy (green). All images depicted in the associated figure are the authors’ own and not taken from another source